Login to Your Account



NEWCO NEWS
About 13 years ago, when Amber Salzman's son and two nephews were diagnosed with adrenoleukodystrophy (ALD), a genetic brain disorder, she didn't know much about rare diseases at all. That's changed for the CEO of Paris-based AAVLife, which – with $12 million in series A money – is taking aim at another: Friedreich's ataxia (FA).

When investors think about funding investigative treatments for sleep apnea, the last thing they're likely to consider is a pill. But that's exactly what Galleon Pharmaceuticals Inc. is pursuing for the indication.

Just a year out of the gate, Atlas Venture-backed Spero Therapeutics LLC snagged Roche AG as a partner to develop anti-infectives for drug-resistant bacterial infections, targeting a pathway that involves both virulence and persistence of gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa).
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: